Fortress Biotech, Inc.

FBIO • Biotechnology

$2.72

▲ +0.01 (+0.37%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$86.47M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Stable or improving margins · 10.8%Reasonable earnings multiple · 14.98Healthy liquidity · 2.49Negative growth trend

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:26 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.72

Change0.37%

Shares Out31.79M

Market Cap$86.47M

Enterprise Value$-56.79M

52W Range1.97 - 4.53

Beta1.21

P/E0.79

P/S1.28

P/B0.53

P/FCF0.47

EV/Sales-0.84

Price$2.72

Change0.37%

Shares Out31.79M

Market Cap$86.47M

Enterprise Value$-56.79M

52W Range1.97 - 4.53

Beta1.21

P/E0.79

P/S1.28

P/B0.53

P/FCF0.47

EV/Sales-0.84

EV/EBITDA8.15

EV/FCF-0.31

Earnings Yield126.99%

FCF Yield214.17%

Dividend Yield0.44%

Gross Margin66.92%

Oper. Margin-111.00%

Profit Margin10.77%

Debt/Eq1.49

Current Ratio2.49

Quick Ratio2.30

Target$5.00

Target Upside83.82%

Target Median$5.00

Target Range5.00 - 5.00

Volume1.39M

Avg Volume510.07K

EPS Surprise3.04

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

57/100

Financial Strength

Debt, cash, stability

63/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

85/100

Why this score▼

Stable or improving margins · 10.8%Reasonable earnings multiple · 14.98Healthy liquidity · 2.49Negative growth trend

Analyst view

Analyst sentiment and price target

FBIO

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$5.00

Mean

$5.00

Median

$5.00

High

$5.00

Company Overview

IPO: 11/17/2011

Industry: Biotechnology

P/B i: 0.53

Debt / Equity i: 1.49

Operating Margin: -111.00%

Net Margin: 10.77%

ROE i: -

ROIC: -

Financial Health

Score13 / 20

Debt / Equity: 1.49

Current Ratio: 2.49

Quick Ratio: 2.30

Status: Good

Insider Transactions

Recent executive and insider activity

Jin David

Transaction: 06/22/2026

BUY

Change

+400,000

Price

Not reported

Filing

06/24/2026

Type

BUY

Jin David

Transaction: 04/01/2026

BUY

Change

+2,967

Price

$2.18

Filing

04/01/2026

Type

BUY

WEISS MICHAEL S

Transaction: 03/18/2026

BUY

Change

+475,424

Price

Not reported

Filing

03/20/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Jin David	BUY	+400,000	Not reported	06/22/2026	06/24/2026
Jin David	BUY	+2,967	$2.18	04/01/2026	04/01/2026
WEISS MICHAEL S	BUY	+475,424	Not reported	03/18/2026	03/20/2026
ROSENWALD LINDSAY A MD	BUY	+475,424	Not reported	03/18/2026	03/20/2026
LOBELL J JAY	BUY	+27,322	Not reported	01/01/2026	01/05/2026
Hoenlein Malcolm	BUY	+27,322	Not reported	01/01/2026	01/05/2026
Lorenz Kevin	BUY	+27,322	Not reported	01/01/2026	01/05/2026
Harvey Jimmie	BUY	+27,322	Not reported	01/01/2026	01/05/2026
Klein Dov	BUY	+27,322	Not reported	01/01/2026	01/05/2026
Jin David	BUY	+2,711	$1.31	10/01/2025	10/02/2025
Jin David	BUY	+5,000	$1.22	04/01/2025	04/01/2025
ROSENWALD LINDSAY A MD	BUY	+454,153	Not reported	01/01/2025	01/03/2025
WEISS MICHAEL S	BUY	+454,153	Not reported	01/01/2025	01/03/2025
Hoenlein Malcolm	BUY	+49,383	Not reported	01/01/2025	01/03/2025
Lorenz Kevin	BUY	+49,383	Not reported	01/01/2025	01/03/2025
Harvey Jimmie	BUY	+49,383	Not reported	01/01/2025	01/03/2025
Lu Lucy	BUY	+49,383	Not reported	01/01/2025	01/03/2025
Klein Dov	BUY	+49,383	Not reported	01/01/2025	01/03/2025
Jin David	BUY	+1,000,000	Not reported	12/19/2024	12/23/2024
Jin David	BUY	+2,625	$1.23	10/01/2024	10/01/2024

About the Company

Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Source - link

Peers

ADAG CRVO GANX IMUX NTRB PMVP RLMD TCRX VXRT XBIT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO ® and UNLOXCYT ™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026. Lindsay A.

GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

Seeking Alpha

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Fortress Biotech, Inc. (NASDAQ: FBIO) concerning possible breaches of fiduciary duties. If you are a current shareholder of FBIO, you can obtain additional information here: https://zlk.com/compensation2/fbio-information-request-form or contact Joseph E.

PRNewsWire

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026.

GlobeNewsWire

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad, a next-generation, once daily, oral URAT1 inhibitor for the treatment of gout. Dotinurad's clinical development program includes two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, as well as the ongoing Phase 2 AMETHYST study, collectively designed to evaluate dotinurad across a broad spectrum of patients with gout, including those with limited treatment options.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.22	2.82	3.04
2026-03-31	0.42	-0.21	-0.63
2025-11-14	-0.43	0.11	0.54
2025-08-14	-0.31	-0.46	-0.15
2025-05-21	-0.44	-1.03	-0.59
2025-03-27	-0.79	-0.53	0.26
2024-11-14	-0.27	-0.76	-0.49
2024-08-13	-1.32	-0.73	0.59
2024-05-15	-2.03	-1.03	1
2024-03-28	-1.97	-0.53	1.44
2023-11-14	-3.53	-0.94	2.59
2023-08-14	-3.9	-3.6	0.3